HQ Function

Prior to its acquisition by Novartis, the Seattle headquarters served as the primary center for Chinook's corporate operations, research and development leadership, and clinical program management.

Notable Features:

Located in the vibrant South Lake Union biotech hub, offering modern laboratory and office facilities conducive to scientific research and collaboration.

Work Culture:

As a clinical-stage biotech, the culture likely emphasized innovation, scientific rigor, a fast-paced environment, and a strong patient-centric mission focused on kidney diseases.

HQ Significance:

The headquarters was central to Chinook's strategy and execution in developing its pipeline of kidney disease therapeutics, including its lead candidates atrasentan and BION-1301.

Values Reflected in HQ: The headquarters likely reflected values of scientific excellence, collaboration, and a dedicated focus on addressing unmet medical needs in kidney disease.

Location:

Prior to its acquisition by Novartis, Chinook Therapeutics' primary operational presence was in North America, with key offices in Seattle (WA, USA), Vancouver (BC, Canada), and Berkeley (CA, USA). Its clinical trials for drug candidates were conducted globally, involving trial sites in various countries to reach diverse patient populations for its rare kidney disease programs. The company's focus was on global drug development and potential commercialization.

Street Address:

400 Dexter Ave N, Suite 800

City:

Seattle

State/Province:

WA

Country:

USA